HALO
Halozyme Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$110.29
−0.42%Leverage
- Debt / equity
- 14.95x
- Net debt / equity
- 13.82x
- Debt / assets
- 0.83x
- Debt / EBITDA
- 3.01x
- Net debt / EBITDA
- 2.78x
Liquidity & coverage
- Current ratio
- 2.71x
- Quick ratio
- 2.31x
- Cash ratio
- 0.67x
- Interest coverage
- 46.52x
- EBITDA / interest
- 35.17x
- Working capital
- $588.6M
Cash & dividend
- FCF / debt
- 0.38x
- Cash flow / debt
- 0.38x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Leverage, liquidity, debt coverage and shareholder-distribution metrics · Data as of Jun 1, 2026